Image
Improving the diagnosis and patient management of systemic autoinflammatory diseases
vidéo
PlayPlay
vidéo
PlayPlay
previous arrow
next arrow

SAID signature

Identify a common signature to SAID enabling rapid differential diagnosis

SAID characterization

Provide deep characterization of each specific pathogenic pathway and build dedicated analysis kits

SAID diagnosis

Build a robust algorithm enabling reliable triage among the whole SAID spectrum

 

What are guSAID?

Find out more on the different kind of auto-inflammatory disease for which diagnosis is missing

 

 

Find a center!

Identify the recruitment centre closest to you

 

 

Follow the science

Discover the current hot topics that are investigated in the SAID field

 

Paediatric multisystem inflammatory syndrome (PIMS): catching-up with the latest findings on this new disease.

The coronavirus pandemic has brought to light a new autoinflammatory condition that affects children: the paediatric multisystem inflammatory syndrome (PIMS). Pr Alexandre Belot, paediatric rheumatologist, tells us more about the symptoms of this disease, the treatments and the protective effect of vaccination on this pathology.

2022.06.07 ImmunAID illustration ABelot x500

How would you define PIMS (Paediatric multisystem inflammatory syndrome)? What are the most obvious symptoms to recognize this disease?

It is a new disease that appeared a few months after the first wave of the pandemic and affects only children, the average age is 8 years. Some of the symptoms are similar to those observed in patients with Kawasaki disease: high fevers, cheilitis, conjunctivitis, fatigue with digestive syndromes (diarrhea and abdominal pain) and a positive serology to SARS-COV-2 which closely links the appearance of this disease to a recent COVID 19. PIMS is a post-infectious inflammatory disease, occurring about 4 weeks after the acute infection.

To date, has it been possible to identify an effective treatment for this disease?

Following Kawasaki diseases guideline, in France, two kinds of treatments have been tested and compared: IVIG (intravenous immunoglobulin) alone and IVIG associated with corticosteroids. Retrospective data from 106 patients were collected and analyzed using a propensity score to compare the efficacy of these two approaches and it was found that the combination of corticosteroids was more effective as there was a reduction in the persistence of fever in these patients compared to those who received IVIG alone. These results were later confirmed by other groups.

Have we been able to identify biological markers for this disease?

For this new disease, we still lack markers but of course studies are underway.

A first specific marker has been identified recently: it is a marker associated to the immune T cells response, called V.  In more than 75% of cases, Vis expanded and it is a hallmark of the PIMS. This marker can already be used to help for the differential diagnosis.

Finally, what is the role of COVID-19 vaccination in this disease? Can we already see a protective role of the vaccine?

Studies have already demonstrated the protective role of the vaccine, including a study conducted last year that showed that out of 33 children with PIMS, 26 were unvaccinated and 7 had received a dose of the vaccine, so none were fully vaccinated, which already presents signals in favor of the vaccine.

Other studies are also currently underway, and the results clearly point in the same direction. So, I encourage pediatricians to promote vaccination to parents

Countries

12

Countries

Funding

16 M€

Funding

Years

5

Years

Partners

25

Partners

Hospitals

37

Hospitals